大型抑郁障碍的辅助卡里普拉:系统性审查和元分析
Hartej Gill1,2, David C J Chen-Li1,2, Sipan Haikazian1,2
1Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
CNS spectrums
|March 31, 2024
概括
卡里普拉辛是一种第二代抗精神病药物,当添加到抗抑郁药时,可能会改善主要抑郁障碍 (MDD) 的治疗反应. 虽然它显示出显著的响应率,但缓解率在统计上并不显著,这表明需要进一步研究.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 大型抑郁症 (MDD) 往往需要对患者进行治疗增强,因为患者对一线抗抑郁药物反应不完全.
- 第二代非典型抗精神病药物 (SGA) 越来越多地被探索为增强策略.
- 卡里普拉是最近批准的SGA用于MDD增强.
研究的目的:
- 评估卡里普拉辛作为重度抑郁障碍增强治疗的疗效.
- 评估连续 (症状严重程度) 和分类 (缓解和反应率) 的结果.
- 通过元分析综合随机对照试验 (RCT) 的证据.
主要方法:
- 四个RCT的系统审查和元分析以及五项额外研究的定性审查.
- 与安慰剂相比,治疗反应和缓解率的风险比率 (RRs) 的计算.
- 分析所有原因中断率作为可接受性的衡量标准.
- 计算抑郁症状严重程度的标准化平均差异 (SMD) (MADRS分数).
主要成果:
- 卡里普拉辛增强显示了治疗响应的统计学显著改善 (RR:1.21,P=0.008).
- 一项研究表明,与安慰剂相比,卡里普拉可以缓解抑郁症状.
- 综合缓解率在统计上没有显著性 (RR:0.99,P=0.91).
- 观察到中等程度的抗抑郁作用 (在MADRS得分中的SMD:-1.79).
结论:
- 卡里普拉显示出作为MDD有效增强治疗的潜力,特别是在改善应答率方面.
- 证据表明卡里普拉对缓解率的影响需要进一步调查.
- 需要进行更多的研究才能充分阐明卡里普拉在MDD治疗中的作用.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
01:25Antidepressant Drugs: Overview
467
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
467
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
382
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
382
01:28Psychosis and Antipsychotic Drugs: Overview
248
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
248
01:18Depression: Overview
242
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
242
01:26Psychosis: Goals of Pharmacotherapy
125
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
125